Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promising preclinical and clinical activity against metastatic colorectal cancer, particularly in combination with chemotherapy. METHODS: Of 813 patients with previously untreated metastatic colorectal cancer, we randomly assigned 402 to receive irinotecan, bolus fluorouracil, and leucovorin (IFL) plus bevacizumab (5 mg per kilogram of body weight every two weeks) and 411 to receive IFL plus placebo. The primary end point was overall survival. Secondary end points were progression-free survival, the response rate, the duration of the response, safety, and the quality of life. RESULTS: The median duration of survival was 20.3 months in the group given IFL plus bevacizumab, as compared with 15.6 months in the group given IFL plus placebo, corresponding to a hazard ratio for death of 0.66 (P<0.001). The median duration of progression-free survival was 10.6 months in the group given IFL plus bevacizumab, as compared with 6.2 months in the group given IFL plus placebo (hazard ratio for disease progression, 0.54; P<0.001); the corresponding rates of response were 44.8 percent and 34.8 percent (P=0.004). The median duration of the response was 10.4 months in the group given IFL plus bevacizumab, as compared with 7.1 months in the group given IFL plus placebo (hazard ratio for progression, 0.62; P=0.001). Grade 3 hypertension was more common during treatment with IFL plus bevacizumab than with IFL plus placebo (11.0 percent vs. 2.3 percent) but was easily managed. CONCLUSIONS: The addition of bevacizumab to fluorouracil-based combination chemotherapy results in statistically significant and clinically meaningful improvement in survival among patients with metastatic colorectal cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Necrosis promotes the expression of VEGFa, as dying tumor cells release signals that stimulate the growth of new blood vessels33,53.”
From Self-supervised learning reveals clinically relevant histomorphological patterns for therapeutic strategies in colon cancer (2025) · cites this paper as [33]
In the citing paper
“Subsequently, as several phase III trials had demonstrated that FOLFOX and XELOX are comparable in the context of metastatic colorectal cancer33–35”
From Self-supervised learning reveals clinically relevant histomorphological patterns for therapeutic strategies in colon cancer (2025) · cites this paper as [33]
In the citing paper
“It has been reported that increased SFK expression occurs in approximately 80% of CRC specimens when compared to the normal adjacent colonic epithelium (Hurwitz et al., 2004).”
From Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab (2011) · cites this paper as Hurwitz et al., 2004
In the citing paper
“The median overall survival in the IFL and bevacizumab arm was 20.3 months versus 15.6 months in the IFL alone arm.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [46]
In the citing paper
“The anti-VEGF antibody bevacizumab (BEV) is used in combination with chemotherapy (FOLFOX or FOLFIRI) for the treatment of mCRC with activating mutations in the RAS/RAF/MAPK pathway [121].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [121]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Self-citationKim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Self-citationIrinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Self-citationYang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Goldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Pitot, H. C., & Alberts, S. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,249
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966
Kabbinavar, F., Hurwitz, H. I., Fehrenbacher, L., Meropol, N. J., Novotny, W. F., Lieberman, G., Griffing, S., & Bergsland, E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.066 · Cited by 1,716
Self-citation
Research works printed but not linked: 4
- Presta LG, 1997, Cancer Res, 57, 4593
- Nissen NN, 1998, Am J Pathol, 152, 1445
- Hurwitz H, 2002, Prog Proc Am Soc Clin Oncol, 21, 82
- Benson AB, 2003, Prog Proc Am Soc Clin Oncol, 22, 243
Cited by
Items 801–900 of 1,082
Lu, C., Bonome, T., Li, Y., Kamat, A. A., Han, L. Y., Schmandt, R., Coleman, R. L., Gershenson, D. M., Jaffe, R. B., Birrer, M. J., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3700 · Cited by 182
“48 late-stage (III and IV), high-grade (3) microdissected papillary serous”
BackgroundThe VEGF family in cancer and antibody-based strategies for their inhibition
Sullivan, L. A., & Brekken, R. A. (2010) · mAbs · doi:10.4161/mabs.2.2.11360 · Cited by 181
Chemoradiotherapy for Rectal Cancer: An Updated Analysis of Factors Affecting Pathological Response
Sanghera, P., Wong, D. W. Y., McConkey, C. C., Geh, J. I., & Hartley, A. (2008) · Clinical Oncology · doi:10.1016/j.clon.2007.11.013 · Cited by 182
GAUDREAULT, J., FEI, D., BEYER, J. C., RYAN, A., RANGELL, L., SHIU, V., & DAMICO, L. A. (2007) · Retina · doi:10.1097/iae.0b013e318134eecd · Cited by 181
Berlin, J., Bendell, J. C., Hart, L. L., Firdaus, I., Gore, I., Hermann, R. C., Mulcahy, M. F., Zalupski, M. M., Mackey, H. M., Yauch, R. L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1800 · Cited by 181
Self-citationA Review on Bevacizumab and Surgical Wound Healing: An Important Warning to All Surgeons
Gordon, C. R., Rojavin, Y., Patel, M., Zins, J. E., Grana, G., Kann, B., Simons, R., & Atabek, U. (2009) · Annals of Plastic Surgery · doi:10.1097/sap.0b013e3181828141 · Cited by 181
Brown, D. B., Nikolic, B., Covey, A. M., Nutting, C. W., Saad, W. E. A., Salem, R., Sofocleous, C. T., & Sze, D. Y. (2012) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2011.11.029 · Cited by 182
Role of the VEGF/VEGFR Axis in Cancer Biology and Therapy
(2012) · Advances in Cancer Research · doi:10.1016/b978-0-12-386503-8.00006-5 · Cited by 180
Karlsson, H., Fryknäs, M., Larsson, R., & Nygren, P. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.03.026 · Cited by 180
INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR CENTRAL AND HEMICENTRAL RETINAL VEIN OCCLUSIONS: IBeVO Study
COSTA, R. A., JORGE, R., CALUCCI, D., MELO, L. A., CARDILLO, J. A., & SCOTT, I. U. (2007) · Retina · doi:10.1097/iae.0b013e31802eff83 · Cited by 180
Glioma and glioblastoma - how much do we (not) know?
JOVČEVSKA, I., KOČEVAR, N., & KOMEL, R. (2013) · Molecular and Clinical Oncology · doi:10.3892/mco.2013.172 · Cited by 180
Trarbach, T., Moehler, M., Heinemann, V, Köhne, C.-H., Przyborek, M., Schulz, C., Sneller, V, Gallant, G., & Kanzler, S. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605507 · Cited by 180
Kabbinavar, F. F., Hurwitz, H. I., Yi, J., Sarkar, S., & Rosen, O. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7931 · Cited by 180
Self-citationVascular endothelial growth factor biology: clinical implications for ocular treatments
Bhisitkul, R. B. (2006) · British Journal of Ophthalmology · doi:10.1136/bjo.2006.098426 · Cited by 181
The role of blood platelets in tumor angiogenesis
Sabrkhany, S., Griffioen, A. W., & oude Egbrink, M. G. A. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.12.001 · Cited by 175
Aziz, M. A., Serya, R. A. T., Lasheen, D. S., Abdel-Aziz, A. K., Esmat, A., Mansour, A. M., Singab, A. N. B., & Abouzid, K. A. M. (2016) · Scientific Reports · doi:10.1038/srep24460 · Cited by 174
Nagl, L., Horvath, L., Pircher, A., & Wolf, D. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00766 · Cited by 180
Management of bevacizumab-associated bowel perforation: a case series and review of the literature
Badgwell, B. D., Camp, E. R., Feig, B., Wolff, R. A., Eng, C., Ellis, L. M., & Cormier, J. N. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm508 · Cited by 180
Endothelial Cells in the Tumor Microenvironment
Sobierajska, K., Ciszewski, W. M., Sacewicz-Hofman, I., & Niewiarowska, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-37184-5_6 · Cited by 179
S3-Leitlinie Kolorektales Karzinom Version 1.0 - Juni 2013 AWMF-Registernummer: 021/007OL
Pox, C., Aretz, S., Bischoff, S., Graeven, U., Hass, M., Heußner, P., Hohenberger, W., Holstege, A., Hübner, J., Kolligs, F., et al. (2013) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0033-1350264 · Cited by 179
Quenet, F., Goéré, D., Mehta, S. S., Roca, L., Dumont, F., Hessissen, M., Saint-Aubert, B., & Elias, D. (2011) · Annals of Surgery · doi:10.1097/sla.0b013e3182263933 · Cited by 180
ZD6474 – a novel inhibitor of VEGFR and EGFR tyrosine kinase activity
Ryan, A. J., & Wedge, S. R. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602603 · Cited by 177
Goldman, D. P., Shang, B., Bhattacharya, J., Garber, A. M., Hurd, M., Joyce, G. F., Lakdawalla, D. N., Panis, C., & Shekelle, P. G. (2005) · Health Affairs · doi:10.1377/hlthaff.w5.r5 · Cited by 178
Cytokine-Mediated Crosstalk between Immune Cells and Epithelial Cells in the Gut
Mahapatro, M., Erkert, L., & Becker, C. (2021) · Cells · doi:10.3390/cells10010111 · Cited by 177
Hurwitz, H., & Saini, S. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.08.001 · Cited by 179
Self-citationNanoformulations for combination or cascade anticancer therapy
Miao, L., Guo, S., Lin, C. M., Liu, Q., & Huang, L. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.003 · Cited by 178
Bevacizumab: A Review of Its Use in Advanced Cancer
Keating, G. M. (2014) · Drugs · doi:10.1007/s40265-014-0302-9 · Cited by 177
Challenges in monoclonal antibody-based therapies
Samaranayake, H., Wirth, T., Schenkwein, D., Räty, J. K., & Ylä-Herttuala, S. (2009) · Annals of Medicine · doi:10.1080/07853890802698842 · Cited by 178
Hecht, J. R., Trarbach, T., Hainsworth, J. D., Major, P., Jäger, E., Wolff, R. A., Lloyd-Salvant, K., Bodoky, G., Pendergrass, K., Berg, W., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.4496 · Cited by 178
Self-citationVEGF-VEGFR Signals in Health and Disease
Shibuya, M. (2014) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2013.113 · Cited by 177
Cancer and thrombosis: from molecular mechanisms to clinical presentations
BULLER, H. R., VAN DOORMAAL, F. F., VAN SLUIS, G. L., & KAMPHUISEN, P. W. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02497.x · Cited by 177
Glycosaminoglycan modification of neuropilin‐1 modulates VEGFR2 signaling
Shintani, Y., Takashima, S., Asano, Y., Kato, H., Liao, Y., Yamazaki, S., Tsukamoto, O., Seguchi, O., Yamamoto, H., Fukushima, T., et al. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601188 · Cited by 167
Stockler, M. R., Hilpert, F., Friedlander, M., King, M. T., Wenzel, L., Lee, C. K., Joly, F., de Gregorio, N., Arranz, J. A., Mirza, M. R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4240 · Cited by 178
Kesmodel, S. B., Ellis, L. M., Lin, E., Chang, G. J., Abdalla, E. K., Kopetz, S., Vauthey, J.-N., Rodriguez-Bigas, M. A., Curley, S. A., & Feig, B. W. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7857 · Cited by 177
Tumoral Drug Metabolism: Overview and Its Implications for Cancer Therapy
Michael, M., & Doherty, M. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.120 · Cited by 177
Cunha, S. I., Pardali, E., Thorikay, M., Anderberg, C., Hawinkels, L., Goumans, M.-J., Seehra, J., Heldin, C.-H., ten Dijke, P., & Pietras, K. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091309 · Cited by 177
Hu, H., Hang, J.-J., Han, T., Zhuo, M., Jiao, F., & Wang, L.-W. (2016) · Tumor Biology · doi:10.1007/s13277-015-4741-z · Cited by 177
Apoptosis and colorectal cancer
Watson, A. J. M. (2004) · Gut · doi:10.1136/gut.2004.052704 · Cited by 177
Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia
Rapisarda, A., & Melillo, G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.64 · Cited by 176
Monoclonal antibodies in the treatment of metastatic colorectal cancer: A review
Tol, J., & Punt, C. J. A. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.03.012 · Cited by 176
O'Connor, J. P., Jackson, A., Asselin, M.-C., Buckley, D. L., Parker, G. J., & Jayson, G. C. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70196-7 · Cited by 174
The Notch pathway in colorectal cancer
Vinson, K. E., George, D. C., Fender, A. W., Bertrand, F. E., & Sigounas, G. (2016) · International Journal of Cancer · doi:10.1002/ijc.29800 · Cited by 175
Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis
Jubb, A. M., Buffa, F. M., & Harris, A. L. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00944.x · Cited by 175
Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies
Satoh, M., Iida, S., & Shitara, K. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.11.1161 · Cited by 175
Angiomotin Regulates Endothelial Cell-Cell Junctions and Cell Motility
Bratt, A., Birot, O., Sinha, I., Veitonmäki, N., Aase, K., Ernkvist, M., & Holmgren, L. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503915200 · Cited by 175
Pragmatic issues in biomarker evaluation for targeted therapies in cancer
de Gramont, A., Watson, S., Ellis, L. M., Rodón, J., Tabernero, J., de Gramont, A., & Hamilton, S. R. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.202 · Cited by 176
Pathological angiogenesis and inflammation in tissues
Jeong, J.-H., Ojha, U., & Lee, Y. M. (2021) · Archives of Pharmacal Research · doi:10.1007/s12272-020-01287-2 · Cited by 174
Guo, X., Yi, H., Li, T. C., Wang, Y., Wang, H., & Chen, X. (2021) · Biomolecules · doi:10.3390/biom11020253 · Cited by 172
Receptor Tyrosine Kinase-Mediated Angiogenesis
Jeltsch, M., Leppanen, V.-M., Saharinen, P., & Alitalo, K. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009183 · Cited by 175
International Journal of Clinical Oncology
(2013) · International Journal of Clinical Oncology · doi:10.1007/10147.1437-7772 · Cited by 175
Dopamine Increases the Efficacy of Anticancer Drugs in Breast and Colon Cancer Preclinical Models
Sarkar, C., Chakroborty, D., Chowdhury, U. R., Dasgupta, P. S., & Basu, S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1778 · Cited by 174
Maitland, M. L., Kasza, K. E., Karrison, T., Moshier, K., Sit, L., Black, H. R., Undevia, S. D., Stadler, W. M., Elliott, W. J., & Ratain, M. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0058 · Cited by 174
Why all randomised controlled trials produce biased results
Krauss, A. (2018) · Annals of Medicine · doi:10.1080/07853890.2018.1453233 · Cited by 175
Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases
Chun, Y. S., Laurent, A., Maru, D., & Vauthey, J.-N. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70064-6 · Cited by 173
Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas
Desjardins, A., Reardon, D. A., Herndon, J. E., Marcello, J., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Sampson, J., Bailey, L., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0260 · Cited by 173
Masi, G., Salvatore, L., Boni, L., Loupakis, F., Cremolini, C., Fornaro, L., Schirripa, M., Cupini, S., Barbara, C., Safina, V., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv012 · Cited by 172
VEGF/VEGFR signalling as a target for inhibiting angiogenesis
Kiselyov, A., Balakin, K. V., & Tkachenko, S. E. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.1.83 · Cited by 172
Schiller, J. H., Larson, T., Ou, S.-H. I., Limentani, S., Sandler, A., Vokes, E., Kim, S., Liau, K., Bycott, P., Olszanski, A. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.8355 · Cited by 172
Reddy, S. K., Morse, M. A., Hurwitz, H. I., Bendell, J. C., Gan, T. J., Hill, S. E., & Clary, B. M. (2008) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2007.06.290 · Cited by 172
Self-citationNapabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial
Jonker, D. J., Nott, L., Yoshino, T., Gill, S., Shapiro, J., Ohtsu, A., Zalcberg, J., Vickers, M. M., Wei, A. C., Gao, Y., et al. (2018) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(18)30009-8 · Cited by 172
Rapisarda, A., Hollingshead, M., Uranchimeg, B., Bonomi, C. A., Borgel, S. D., Carter, J. P., Gehrs, B., Raffeld, M., Kinders, R. J., Parchment, R., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0274 · Cited by 171
Park, M. S., Ravi, V., & Araujo, D. M. (2010) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32833aaad4 · Cited by 172
Refractoriness to Antivascular Endothelial Growth Factor Treatment: Role of Myeloid Cells
Shojaei, F., & Ferrara, N. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0925 · Cited by 171
Self-citationNathan, P., Zweifel, M., Padhani, A. R., Koh, D.-M., Ng, M., Collins, D. J., Harris, A., Carden, C., Smythe, J., Fisher, N., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3376 · Cited by 170
Drug resistance, predictive markers and pharmacogenomics in colorectal cancer
Longley, D. B., Allen, W. L., & Johnston, P. G. (2006) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.08.001 · Cited by 171
Grothey, A., Hedrick, E. E., Mass, R. D., Sarkar, S., Suzuki, S., Ramanathan, R. K., Hurwitz, H. I., Goldberg, R. M., & Sargent, D. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.8099 · Cited by 171
Self-citationCorreale, P., Cusi, M. G., Tsang, K. Y., Del Vecchio, M. T., Marsili, S., Placa, M. L., Intrivici, C., Aquino, A., Micheli, L., Nencini, C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.147 · Cited by 171
Ottaiano, A., Franco, R., Aiello Talamanca, A., Liguori, G., Tatangelo, F., Delrio, P., Nasti, G., Barletta, E., Facchini, G., Daniele, B., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2142 · Cited by 171
The Role of Wnt Signalling in Angiogenesis.
Olsen, J. J., Pohl, S., Deshmukh, A. P., Visweswaran, M., Ward, N. C., Arfuso, F., Agostino, M., & Dharmarajan, A. (2017) · Europe PMC (PubMed Central) · Cited by 234
Niu, Z., Jin, R., Zhang, Y., & Li, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01200-x · Cited by 170
“In 2004, bevacizumab was approved by the FDA for the treatment of metastatic colorectal cancer based on the results of AVF2107 clinical trial.(145) However, as the benefits of bevacizumab extended to other malignancies, including non-squamous NSCLC, renal cell carcinoma, ovarian cancer, and cervical cancer,(142) LSCC…”
MethodColorectal cancer: Recent advances in management and treatment
Fadlallah, H., El Masri, J., Fakhereddine, H., Youssef, J., Chemaly, C., Doughan, S., & Abou-Kheir, W. (2024) · World Journal of Clinical Oncology · doi:10.5306/wjco.v15.i9.1136 · Cited by 169
“…III trial demonstrated that the combination of bevacizumab with irinotecan, fluorouracil, and leucovorin (IFL) compared to IFL alone yielded a higher overall survival (median OS: 20.3 months vs 15.6 months; P < 0.001) and longer PFS (PFS: 10.6 months vs 6.2 months; P < 0.001) in mCRC patients[115].”
InfluentialRenal Effects of Anti-angiogenesis Therapy: Update for the Internist
Gurevich, F., & Perazella, M. A. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.11.025 · Cited by 170
Stipa, F., Chessin, D. B., Shia, J., Paty, P. B., Weiser, M., Temple, L. K. F., Minsky, B. D., Wong, W. D., & Guillem, J. G. (2006) · Annals of Surgical Oncology · doi:10.1245/aso.2006.03.053 · Cited by 173
A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer
Rosen, L. S., Hurwitz, H. I., Wong, M. K., Goldman, J., Mendelson, D. S., Figg, W. D., Spencer, S., Adams, B. J., Alvarez, D., Seon, B. K., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0098 · Cited by 170
Self-citationCurrent treatment for colorectal liver metastases
Misiakos, E. P. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i36.4067 · Cited by 170
Scholz, A., Harter, P. N., Cremer, S., Yalcin, B. H., Gurnik, S., Yamaji, M., Di Tacchio, M., Sommer, K., Baumgarten, P., Bähr, O., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505505 · Cited by 169
Helfrich, I., Scheffrahn, I., Bartling, S., Weis, J., von Felbert, V., Middleton, M., Kato, M., Ergün, S., Augustin, H. G., & Schadendorf, D. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091846 · Cited by 170
INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
EMERSON, M. V., LAUER, A. K., FLAXEL, C. J., WILSON, D. J., FRANCIS, P. J., STOUT, J. T., EMERSON, G. G., SCHLESINGER, T. K., NOLTE, S. K., & KLEIN, M. L. (2007) · Retina · doi:10.1097/iae.0b013e31804b3e15 · Cited by 170
Rini, B. I. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1989 · Cited by 169
Parks, R., Gonen, M., Kemeny, N., Jarnagin, W., D’Angelica, M., DeMatteo, R., Garden, J. O., Blumgart, L. H., & Fong, Y. (2007) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2006.12.036 · Cited by 161
Lang, S. A., Gaumann, A., Koehl, G. E., Seidel, U., Bataille, F., Klein, D., Ellis, L. M., Bolder, U., Hofstaedter, F., Schlitt, H., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22442 · Cited by 169
Toffoli, G., Cecchin, E., Gasparini, G., D'Andrea, M., Azzarello, G., Basso, U., Mini, E., Pessa, S., De Mattia, E., Lo Re, G., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6125 · Cited by 169
Apelin is a potent activator of tumour neoangiogenesis
Sorli, S. C., Le Gonidec, S., Knibiehler, B., & Audigier, Y. (2007) · Oncogene · doi:10.1038/sj.onc.1210573 · Cited by 169
Choi, K. Y., Jeon, E. J., Yoon, H. Y., Lee, B. S., Na, J. H., Min, K. H., Kim, S. Y., Myung, S.-J., Lee, S., Chen, X., et al. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.05.029 · Cited by 169
New Angiogenic Regulators Produced by TAMs: Perspective for Targeting Tumor Angiogenesis
Larionova, I., Kazakova, E., Gerashchenko, T., & Kzhyshkowska, J. (2021) · Cancers · doi:10.3390/cancers13133253 · Cited by 166
“Bevacizumab (Avastin), a VEGF-A targeting monoclonal antibody, was the first angiogenesis inhibitor approved by FDA in 2004 for the treatment of metastatic colorectal cancer (mCRC) in combination with chemotherapy [211,212].”
BackgroundThe Colorectal Cancer Tumor Microenvironment and Its Impact on Liver and Lung Metastasis
Chandra, R., Karalis, J. D., Liu, C., Murimwa, G. Z., Voth Park, J., Heid, C. A., Reznik, S. I., Huang, E., Minna, J. D., & Brekken, R. A. (2021) · Cancers · doi:10.3390/cancers13246206 · Cited by 167
“[46] showed that the addition of bevacizumab, an anti-VEGF agent, to standard chemotherapy improved the median survival of patients with mCRC; however, the majority of patients did not exhibit a response to therapy [46].”
BackgroundD’Angelica, M., Kornprat, P., Gonen, M., Chung, K.-Y., Jarnagin, W. R., DeMatteo, R. P., Fong, Y., Kemeny, N., Blumgart, L. H., & Saltz, L. B. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-006-9074-0 · Cited by 168
Van Geelen, C. M. M., de Vries, E. G. E., & de Jong, S. (2004) · Drug Resistance Updates · doi:10.1016/j.drup.2004.11.002 · Cited by 168
The Price We Pay for Progress: A Meta-Analysis of Harms of Newly Approved Anticancer Drugs
Niraula, S., Seruga, B., Ocana, A., Shao, T., Goldstein, R., Tannock, I. F., & Amir, E. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.3824 · Cited by 167
Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars
Rosen, L. S., Jacobs, I. A., & Burkes, R. L. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0518-1 · Cited by 168
Biomarkers for gastric cancer: prognostic, predictive or targets of therapy?
Durães, C., Almeida, G. M., Seruca, R., Oliveira, C., & Carneiro, F. (2014) · Virchows Archiv · doi:10.1007/s00428-013-1533-y · Cited by 168
Whole Cell Vaccines—Past Progress and Future Strategies
Keenan, B. P., & Jaffee, E. M. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.02.007 · Cited by 165
Role of myeloid cells in tumor angiogenesis and growth
Shojaei, F., Zhong, C., Wu, X., Yu, L., & Ferrara, N. (2008) · Trends in Cell Biology · doi:10.1016/j.tcb.2008.06.003 · Cited by 167
Self-citationLessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer
Jain, R. K. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2346 · Cited by 165
Schmoll, H.-J., Twelves, C., Sun, W., O'Connell, M. J., Cartwright, T., McKenna, E., Saif, M., Lee, S., Yothers, G., & Haller, D. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70486-3 · Cited by 169
Self-citationAdjuvant therapy in colon cancer—what, when and how?
Chau, I., & Cunningham, D. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl029 · Cited by 167
Das, P., Skibber, J. M., Rodriguez-Bigas, M. A., Feig, B. W., Chang, G. J., Hoff, P. M., Eng, C., Wolff, R. A., JanJan, N. A., Delclos, M. E., et al. (2006) · American Journal of Clinical Oncology · doi:10.1097/01.coc.0000214930.78200.4a · Cited by 166
Putcha, G. V., Bejjani, B. A., Bleoo, S., Booker, J. K., Carey, J. C., Carson, N., Das, S., Dempsey, M. A., Gastier-Foster, J. M., Greinwald, J. H., et al. (2007) · Genetics in Medicine · doi:10.1097/gim.0b013e3180a03276 · Cited by 167
Harrop, R., Connolly, N., Redchenko, I., Valle, J., Saunders, M., Ryan, M. G., Myers, K. A., Drury, N., Kingsman, S. M., Hawkins, R. E., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2732 · Cited by 166
Cardiac Toxicity From Systemic Cancer Therapy: A Comprehensive Review
Curigliano, G., Mayer, E. L., Burstein, H. J., Winer, E. P., & Goldhirsch, A. (2010) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2010.05.006 · Cited by 166
Metadata
- Authors
- Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., Ferrara, N., Fyfe, G., Rogers, B., Ross, R., & Kabbinavar, F.
- Affiliations
- Duke University (US)
- Kaiser Permanente (US)
- Genentech (US)
- Sarah Cannon (US)
- Hematology and Oncology Associates of Northeastern Pennsylvania (US)
- Vanderbilt University (US)
- California Pacific Medical Center (US)
- University of California, Los Angeles (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-06-03
- Volume
- 350
- Issue
- 23
- Pages
- 2335-2342
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2157769714
- Cited by
- 10,968
- References
- 14
- Citations by year
- 2026: 127 · 2025: 162 · 2024: 242 · 2023: 276 · 2022: 264 · 2021: 270 · 2020: 289 · 2019: 293 · 2018: 323 · 2017: 422 · 2016: 462 · 2015: 523 · 2014: 608 · 2013: 671 · 2012: 711
- FWCI
- 339.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5k23ca085582-06)
- National Cancer Institute (K23 CA085582-04)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- bevacizumab, metastatic colorectal cancer, irinotecan, 5-fluorouracil, leucovorin, anti-VEGF monoclonal antibody, combination chemotherapy, overall survival, progression-free survival, hypertension, first-line therapy
- MeSH terms
- Bevacizumab, Irinotecan, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Leucovorin, Female, Fluorouracil, Humans, Male, Middle Aged, Neoplasm Metastasis, Quality of Life, Colorectal Neoplasms, Survival Analysis, Disease-Free Survival, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.